Biomarker Accelerator Grant Program
CurePSP's Biomarker Accelerator Grant Program funds research to develop and clinically validate biomarkers for earlier diagnosis and improved treatment of progressive supranuclear palsy.
Funder: CurePSP
Due Dates (Anticipated): December 2026 (Letter of Intent) | March 2027 (Full application)
Funding Amounts: Up to $500,000 per award, project duration up to 3 years, no indirect costs allowed.
Summary: Funds research to develop and validate biomarkers for earlier diagnosis and improved treatment of progressive supranuclear palsy (PSP).
Description
The Biomarker Accelerator Grant Program, launched by CurePSP, is a targeted initiative to advance the discovery, validation, and clinical translation of biomarkers for progressive supranuclear palsy (PSP). By supporting projects that bridge laboratory findings and real-world clinical applications, the program seeks to enable earlier and more accurate diagnosis, guide treatment strategies, accelerate clinical research, and improve patient outcomes for PSP. CurePSP aims to catalyze breakthroughs by funding high-impact research that moves promising biomarker discoveries into clinical practice.
